JP2012526852A5 - - Google Patents

Download PDF

Info

Publication number
JP2012526852A5
JP2012526852A5 JP2012511052A JP2012511052A JP2012526852A5 JP 2012526852 A5 JP2012526852 A5 JP 2012526852A5 JP 2012511052 A JP2012511052 A JP 2012511052A JP 2012511052 A JP2012511052 A JP 2012511052A JP 2012526852 A5 JP2012526852 A5 JP 2012526852A5
Authority
JP
Japan
Prior art keywords
patient
genotype
promoter gene
agent
result
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012511052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012526852A (ja
JP6083860B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/034974 external-priority patent/WO2010132817A1/en
Publication of JP2012526852A publication Critical patent/JP2012526852A/ja
Publication of JP2012526852A5 publication Critical patent/JP2012526852A5/ja
Application granted granted Critical
Publication of JP6083860B2 publication Critical patent/JP6083860B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012511052A 2009-05-14 2010-05-14 Ｏｄｃ１の遺伝子型に基づく癌腫診断及び治療 Expired - Fee Related JP6083860B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US21621609P 2009-05-14 2009-05-14
US61/216,216 2009-05-14
US21767909P 2009-06-03 2009-06-03
US21768209P 2009-06-03 2009-06-03
US61/217,682 2009-06-03
US61/217,679 2009-06-03
PCT/US2010/034974 WO2010132817A1 (en) 2009-05-14 2010-05-14 Carcinoma diagnosis and treatments, based on odc1 genotype

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015213116A Division JP2016074672A (ja) 2009-05-14 2015-10-29 Ｏｄｃ１の遺伝子型に基づく癌腫診断及び治療

Publications (3)

Publication Number Publication Date
JP2012526852A JP2012526852A (ja) 2012-11-01
JP2012526852A5 true JP2012526852A5 (https=) 2013-06-27
JP6083860B2 JP6083860B2 (ja) 2017-02-22

Family

ID=43085356

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012511052A Expired - Fee Related JP6083860B2 (ja) 2009-05-14 2010-05-14 Ｏｄｃ１の遺伝子型に基づく癌腫診断及び治療
JP2015213116A Pending JP2016074672A (ja) 2009-05-14 2015-10-29 Ｏｄｃ１の遺伝子型に基づく癌腫診断及び治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015213116A Pending JP2016074672A (ja) 2009-05-14 2015-10-29 Ｏｄｃ１の遺伝子型に基づく癌腫診断及び治療

Country Status (15)

Country Link
US (4) US8329636B2 (https=)
EP (1) EP2430452B1 (https=)
JP (2) JP6083860B2 (https=)
CN (1) CN102483415B (https=)
AU (1) AU2010248803B2 (https=)
CA (1) CA2761946A1 (https=)
DK (1) DK2430452T3 (https=)
ES (1) ES2507145T3 (https=)
HR (1) HRP20140887T1 (https=)
IL (1) IL216369B (https=)
PL (1) PL2430452T3 (https=)
PT (1) PT2430452E (https=)
SI (1) SI2430452T1 (https=)
SM (1) SMT201400177B (https=)
WO (1) WO2010132817A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2430452T3 (da) 2009-05-14 2014-10-06 Univ Arizona State Carcinom-diagnose og behandlinger, baseret på odc1-genotype
CA2799431A1 (en) * 2010-05-14 2011-11-17 Cancer Prevention Pharmaceuticals, Inc. Cancer prevention and treatment methods based on dietary polyamine content
US20120172244A1 (en) 2010-12-20 2012-07-05 Steven Buechler Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease
WO2012088146A2 (en) * 2010-12-20 2012-06-28 The University Of Notre Dame Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease
CA2889711A1 (en) * 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies
WO2015195120A1 (en) * 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
WO2016130918A1 (en) * 2015-02-12 2016-08-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
WO2016149261A1 (en) * 2015-03-16 2016-09-22 Personal Genome Diagnostics, Inc. Systems and methods for analyzing nucleic acid
KR20260033630A (ko) 2015-10-30 2026-03-10 캔서 프리벤션 파마수티컬스, 인코포레이티드 에플로르니틴 및 설린닥, 고정된 용량 조합 제제
WO2017075576A1 (en) 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
JP6963271B2 (ja) * 2017-01-20 2021-11-05 国立大学法人東海国立大学機構 イヌの遺伝性消化管腫瘍症の遺伝子診断法
JP2022532766A (ja) 2019-05-17 2022-07-19 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド 家族性腺腫性ポリポーシスを処置するための方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654349A (en) 1970-05-01 1972-04-04 Merck & Co Inc Substituted indenyl acetic acids
US3647858A (en) 1970-05-01 1972-03-07 Merck & Co Inc Process for preparing 1-benzylidene-3-indenyl acetic acids
US4413141A (en) 1977-07-11 1983-11-01 Merrell Toraude Et Compagnie 2-(Difluoromethyl)-2,5-diaminopentanoic acid
US4330559A (en) 1977-07-11 1982-05-18 Merrell-Toraude Et Cie Method of treating benign prostatic hypertrophy
IL63907A0 (en) 1980-09-24 1981-12-31 Cetus Corp Diagnostic method and antibody probe for use therein
ATE53862T1 (de) 1982-01-22 1990-06-15 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4859452A (en) 1986-01-17 1989-08-22 Board Of Regents, The University Of Texas System Methods for the reduction of difluoromethylornithine associated toxicity
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US4925835A (en) 1986-05-01 1990-05-15 Sloan-Kettering Institute For Cancer Research Aziridinyl putrescine containing compositions and their uses in treating prostate cancer
US5002879A (en) 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
FR2706255B1 (fr) 1993-06-17 1995-10-27 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
EP0754240B1 (en) 1994-02-07 2003-08-20 Beckman Coulter, Inc. Ligase/polymerase-mediated genetic bit analysis of single nucleotide polymorphisms and its use in genetic analysis
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps
CA2325080A1 (en) 1998-03-28 1999-10-07 The Regents Of The University Of California Dfmo and sulindac combination in cancer chemoprevention
US7700568B2 (en) * 1998-06-30 2010-04-20 Sloan-Kettering Institute For Cancer Research Uses of DNA-PK
BR9916536A (pt) * 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
US6753422B2 (en) 1999-03-01 2004-06-22 O'brien Thomas G. Odc allelic analysis method for assessing carcinogenic susceptibility
CA2373931A1 (en) 1999-05-17 2000-11-23 Richard Love Dfmo and celecoxib in combination for cancer chemoprevention and therapy
US6602910B2 (en) 2000-03-07 2003-08-05 Ilex Oncology, Inc. D-enantiomer of DFMO and methods of use therefor
WO2001068076A2 (en) 2000-03-07 2001-09-20 Ilex Oncology, Inc. D-enantiomer of dfmo and methods of use thereof for treating cancer
AU2001285232A1 (en) 2000-08-24 2002-03-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Alpha-difluoromethylornithine (dfmo) use in the human prostate
US7030126B2 (en) 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
WO2007075673A1 (en) 2005-12-20 2007-07-05 University Of Hawaii Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
AU2009333510A1 (en) 2008-12-08 2011-06-30 The Procter & Gamble Company Personal care composition in the form of an article having a hydrophobic surface-resident coating
DK2430452T3 (da) 2009-05-14 2014-10-06 Univ Arizona State Carcinom-diagnose og behandlinger, baseret på odc1-genotype
CA2799431A1 (en) 2010-05-14 2011-11-17 Cancer Prevention Pharmaceuticals, Inc. Cancer prevention and treatment methods based on dietary polyamine content
CA2889711A1 (en) 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies

Similar Documents

Publication Publication Date Title
JP2012526852A5 (https=)
Simpson et al. Pain management in enhanced recovery after surgery (ERAS) protocols
Pergolizzi et al. The pharmacological management of dental pain
Sim et al. Prospective randomized, double‐blind, placebo‐controlled study of pre‐and postoperative administration of a COX‐2‐specific inhibitor as opioid‐sparing analgesia in major colorectal surgery
Sandborn et al. MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized, double‐blind, placebo‐controlled trials
van der Heijde et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty‐two–week, randomized, controlled study
Young et al. Recent advances in multimodal analgesia
Mercadante et al. Pharmacological management of cancer pain in the elderly
Joffe et al. Evaluation and treatment of pain in critically ill adults
Lotia et al. New and emerging medical therapies in Parkinson’s disease
Senek et al. Continuous drug delivery in Parkinson’s disease
Viscusi et al. Peripherally acting mu-opioid receptor antagonists and postoperative ileus: mechanisms of action and clinical applicability
Jain et al. Evaluation of efficacy of oral pregabalin in reducing postoperative pain in patients undergoing total knee arthroplasty
Minkowitz et al. Sufentanil sublingual tablet 30 mcg for the management of pain following abdominal surgery: A randomized, placebo‐controlled, phase‐3 study
Stasiowska et al. Postoperative pain management
Bhaskar et al. Comparison of transdermal diclofenac patch with oral diclofenac as an analgesic modality following multiple premolar extractions in orthodontic patients: a cross over efficacy trial
NO20090887L (no) Fremgangsmate for behandling og forebygging av mukositt
JP2018507910A5 (https=)
Daniels et al. Analgesic efficacy and safety of a novel injectable formulation of diclofenac compared with intravenous ketorolac and placebo after orthopedic surgery: a multicenter, randomized, double-blinded, multiple-dose trial
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
Douzjian et al. Old drug, new route: a systematic review of intravenous acetaminophen after adult cardiac surgery
Seeberger et al. Carbidopa levodopa enteral suspension
Al Dakheel et al. Emerging drugs for levodopa-induced dyskinesia
Aguado et al. The effects of gabapentin on acute opioid tolerance to remifentanil under sevoflurane anesthesia in rats